entertainment -WSS

entertainment

author：knowledge 2025-10-01 22:16:51 - browse：4

Layoff concept illustration of empty desks and people walking away. — Adobe

Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular condensates, laid off 15% of its staff on Tuesday and acknowledged that a pair of collaboration deals with pharma companies had fallen apart.

The downsizing is temporary, CEO Ameet Nathwani told STAT. The company needed to hire new employees with expertise to help move the company’s first drugs into clinical trials and expand its AI capabilities. And with funding for early-stage biotechs still sparse, leadership opted to cut some positions and use the savings to fill new ones over the coming months. Roughly 20 positions were cut.

“We talked to investors right now [about raising more money], and they think that the environment for a preclinical company — it’s not even worth having that discussion,” Nathwani said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease

WSS

Florida health officials providing scant details on measles cases

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

The public health thinking behind the CDC’s new Covid guidance

He's 19 months old and has one of the world’s rarest diseases

In key trial, Verve's treatment lowers cholesterol levels in patients

Does good food count as health care? Study aims to find out

focus

entertainment

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Pregnant women don't need prenatal multivitamins, study concludes

Hepatitis C has a cure — but many Americans still lack access to it

Harvard's David Sinclair gets blowback over aging

Dobbs anniversary: the lost opportunity of abortion as health care

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Trump demands the U.S. pay no more for drugs than other countries … again

Longer MASH drug regimen improved liver, Akero study finds

How to save PrEP access — and even expand it

Anthos stroke drug appears safer than common blood thinner

hotspot

FDA's Woodcock to retire early next year

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Why Talkspace is targeting Medicare, a tricky market

Families look for replacement for GSK asthma drug Flovent

The public health thinking behind the CDC’s new Covid guidance

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

leisure time

leisure time

hotspot

Wikipedia